StockData
Novartis AG logo

Novartis AG

NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Feb 4, 2026Score 7/30
$160.79−0.31 (-0.19%)

Close on Oct 30, 2026Market cap $306.81BP/E 22.5Yield –

Novartis Entresto (sacubitril/valsartan by Year

Entresto (sacubitril/valsartan — chronic heart failure & hypertension) ($M)

Novartis Entresto (sacubitril/valsartan: $7,748M in FY2025, down 0.9% from a year earlier.

Latest, FY2025
7,748
Period ended Dec 31, 2025
Change on a year earlier
-0.9%
7,822 in FY2024
History
9 years
Since FY2017
Sources
8
Documents cited below

Where the FY2025 figure comes from

“|| Entresto | 7 748 | 7 822 | -1 | -2”

Source: Novartis Form 6-K (0001114448-26-000007) ↗

Reported in Form 6-K & Form 20-F.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedEntresto (sacubitril/valsartan — chronic heart failure & hypertension) ($M)Year on yearSource
FY2025Dec 31, 20257,748-0.9%Novartis Form 6-K (0001114448-26-000007) ↗
FY2024Dec 31, 20247,822+29.6%Novartis Form 6-K (0001114448-26-000007) ↗
FY2023Dec 31, 20236,035+30.0%Novartis Form 6-K (0001370368-25-000007) ↗
FY2022Dec 31, 20224,644+30.9%Novartis Form 6-K (0001370368-24-000007) ↗
FY2021Dec 31, 20213,548+42.1%Novartis Form 6-K (0001370368-23-000008) ↗
FY2020Dec 31, 20202,497+44.7%Novartis Form 6-K (0001370368-22-000009) ↗
FY2019Dec 31, 20191,726+67.9%Novartis Form 6-K (0001370368-21-000008) ↗
FY2018Dec 31, 20181,028+102.8%Novartis Form 6-K (0001370368-20-000007) ↗
FY2017Dec 31, 2017507–Novartis Form 6-K (0001370368-19-000006) ↗

Breakdown

What makes up entresto (sacubitril/valsartan

Cite this data

StockData. (2026). Novartis Entresto (sacubitril/valsartan ($M), annual FY2017–FY2025 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/brand-entresto

See every metric in the Novartis KPI table. Data updated Nov 2, 2026.